Modulators of Cytoskeletal Reorganization in CA1 Hippocampal Neurons Show Increased Expression in Patients at Mid-Stage Alzheimer's Disease by Kao, Patricia F. et al.
Boston University
OpenBU http://open.bu.edu
Department of Neurology MED: Neurology Scholarly Works
2010-10-13
Modulators of Cytoskeletal
Reorganization in CA1
Hippocampal Neurons Show
Increased Expression in Patients at
Mid-Stage Alzheimer's Disease
Kao, Patricia F., David A. Davis, Meredith G. Banigan, Charles R. Vanderburg, Sudha
Seshadri, Ivana Delalle. "Modulators of Cytoskeletal Reorganization in CA1
Hippocampal Neurons Show Increased Expression in Patients at Mid-Stage
Alzheimer's Disease" PLoS ONE 5(10): e13337. (2010)
https://hdl.handle.net/2144/3188
Boston University
Modulators of Cytoskeletal Reorganization in CA1
Hippocampal Neurons Show Increased Expression in
Patients at Mid-Stage Alzheimer’s Disease
Patricia F. Kao1, David A. Davis1, Meredith G. Banigan2, Charles R. Vanderburg2, Sudha Seshadri3, Ivana
Delalle1*
1Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America, 2Advanced Tissue Research
Center, Harvard NeuroDiscovery Center, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America, 3Department of Neurology, Boston
University School of Medicine, Boston, Massachusetts, United States of America
Abstract
During the progression of Alzheimer’s disease (AD), hippocampal neurons undergo cytoskeletal reorganization, resulting in
degenerative as well as regenerative changes. As neurofibrillary tangles form and dystrophic neurites appear, sprouting
neuronal processes with growth cones emerge. Actin and tubulin are indispensable for normal neurite development and
regenerative responses to injury and neurodegenerative stimuli. We have previously shown that actin capping protein beta2
subunit, Capzb2, binds tubulin and, in the presence of tau, affects microtubule polymerization necessary for neurite outgrowth
and normal growth cone morphology. Accordingly, Capzb2 silencing in hippocampal neurons resulted in short, dystrophic
neurites, seen in neurodegenerative diseases including AD. Here we demonstrate the statistically significant increase in the
Capzb2 expression in the postmortem hippocampi in persons at mid-stage, Braak and Braak stage (BB) III-IV, non-familial AD in
comparison to controls. The dynamics of Capzb2 expression in progressive AD stages cannot be attributed to reactive
astrocytosis. Moreover, the increased expression of Capzb2 mRNA in CA1 pyramidal neurons in AD BB III-IV is accompanied by
an increased mRNA expression of brain derived neurotrophic factor (BDNF) receptor tyrosine kinase B (TrkB), mediator of
synaptic plasticity in hippocampal neurons. Thus, the up-regulation of Capzb2 and TrkBmay reflect cytoskeletal reorganization
and/or regenerative response occurring in hippocampal CA1 neurons at a specific stage of AD progression.
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Introduction
Genes implicated in the development of AD influence
microtubule and actin filaments responsible for neuronal mor-
phology[1]. The presence of an apolipoprotein E4 allele[2],
correlates with the simplification of dendritic branching patterns in
the brains of AD patients[3]. Consistent with this observation in
human brains, the apolipoprotein E4 inhibits neurite outgrowth in
cultured neuronal cells[4]. Interestingly, amyloid precursor protein
concentrates in lamellipodia where it is proposed to play a role in
growth cone motility and neurite outgrowth[5].
Upon acute neuronal injury, such as axotomy, the first critical
steps that initiate regenerative response are microtubule polymer-
ization and F-actin cytoskeleton rearrangement leading to the
formation of a motile growth cone in a stable axonal segment[6].
Actin cytoskeleton regulator CP (F-actin capping protein, CapZ) is
an a/b heterodimer that binds the barbed end of F-actin thus
blocking the access of actin monomers to the fast growing end.
Both mammalian and Drosophila CP subunits play a critical role in
the organization and dynamics of lamellipodia and filopodia in
non-neuronal cells[7]. One of the mammalian b-subunit isoforms,
Capzb2, is predominantly expressed in the brain[8]. We have
demonstrated that Capzb2 not only caps F-actin barbed end but
also binds bIII-tubulin directly, affecting the rate and the extent of
microtubule polymerization in the presence of tau[9]. Moreover,
Capzb2 - bIII-tubulin interaction is indispensable for normal
growth cone morphology and neurite length[9].
The interaction between CapZ and b-tubulin was uncovered in
a mass spectrometry screen for altered protein-protein interactions
in response to spatial learning[10]. CapZ localization in the
hippocampal dendritic spines has been recently shown to undergo
activity-dependent, synapse-specific regulation in a rat model of
dementia[11]. BDNF is necessary for normal spatial learning[12]
and reduced BDNF and TrkB mRNA levels correlate with
impaired memory performance in senescent rats[13,14]. Further,
lifestyle modifications that are thought to reduce the risk of
developing clinical AD, such as intake of docosahexaenoic acid
(DHA) and increased exercise, appear to interact with BDNF-
related synaptic plasticity[15]. Actin cytoskeleton is a well-
established target for BDNF/TrkB signaling that affects not only
memory formation and retention[16,17] but also neuronal
regeneration[18]. BDNF is required for normal F-actin distribu-
tion in growth cones and for axonal protrusion during regener-
ation in retinal ganglion cells[19].
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13337
As hyperphosphorylated tau gives rise to neurofibrillary tangles
in AD, dystrophic neurites, marked by reduced length and poor
branching, become apparent. In parallel, perisomatic proliferation
of dendrites and sprouting of distal dystrophic neurites take
place[20]. The presence of growth cone-like structures on distal
ends of dystrophic neurites suggests that regenerative response
accompanies degenerative cytoskeletal changes in AD[20]. These
morphological changes in neurons during AD progression indicate
major cytoskeletal reorganization raising the possibility that
microtubules and microfilaments may represent a target for
pathobiological mechanisms underlying AD. Here we report a
significant increase in Capzb2 protein and mRNA levels in
hippocampal CA1 pyramidal neurons at mid-stage non-familial
AD (Braak and Braak, BB, stage III-IV). The up-regulation of
Capzb2 at this stage is accompanied by an increase in mRNA
levels of BDNF primary receptor, TrkB. BDNF/TrkB signaling
modulates cell morphology and neurite length[21,22]. Our data
suggest that Capzb2, a recently established link in microfilament -
microtubule assembly, together with BDNF/TrkB signaling, may
play a role in cytoskeletal reorganization and possibly regenerative
changes at specific stages of AD progression.
Results
Capzb2 protein expression shows a specific increase in
the hippocampal CA1 region in AD BB stage III-IV
We examined Capzb2 protein expression levels in the whole
tissue homogenates of hippocampal CA1 region and prefrontal
cortex (Brodmann area 9) from the brains deposited at the
Massachusetts Alzheimer Disease Research Center (MADRC) in
the Massachusetts General Hospital and from brain autopsies
performed at Boston Medical Center (BM) (Table 1). While
Capzb2 expression remained steady in the prefrontal cortex (PFC)
throughout progressive AD stages, it significantly increased in the
hippocampal CA1 region (HPC) in BBIII-IV (p,0.01; One-way
ANOVA, Figure 1A and 1B). To confirm the specificity of this
increase, we examined, in addition to GAPDH (our loading
control, see Western Blot section in MATERIALS AND METH-
ODS), the expression of another unrelated protein, histone H2b
(His H2b) (Figure 1C). The expression of GAPDH and His H2b in
the examined hippocampi in AD BBI-VI did not change
significantly across stages. We further examined the Capzb2
immunoreactivity in CA1 region in control, AD BBIII-IV and AD
BBV-VI cases (Figure 1D–I). As expected[9], Capzb2 immuno-
reactivity was seen in cytoplasm and neuropil, and appeared most
robust in the cytoplasm of pyramidal neurons in AD BBIII-IV
cases (Figure 1F, arrows).
Since Capzb2 expression is not neuron-specific, we considered
the possibility that the increase in Capzb2 signal might be due to
reactive gliosis. We compared the number of GFAP- immunore-
active astrocytes in CA1 region of BBIII-IV AD and control brains
(Figure 2A, 2B, and 2C). We also examined the GFAP expression
by Western Blot (Figure 2D) and by Luminex analysis using the
capture sandwich immunoassay (Figure 2E). Our results suggest
that the observed increase in Capzb2 expression in the CA1 region
of AD BBIII-IV brains could not be attributed to an increase in
GFAP-immunoreactive glial cells.
The increase in Capzb2 mRNA expression in CA1
pyramidal neurons in AD BBIII-IV is accompanied by the
up-regulation of TrkB mRNA
In order to further elucidate the origin of the Capzb2 expression
increase, we used laser capture microdissection (LCM) to examine
a cell population particularly vulnerable to AD from the selected
cases studied above with protein expression analysis. Visualization
of hippocampal neurons prior to LCM was achieved using
HistoGene stain (Figure S1). To generate cDNA for qPCR
analysis, we obtained RNA from approximately 2, 000 CA1
pyramidal neurons from each of AD BBIII-IV (MADRC-912 and
MADRC-1323) and control brains (BM-16 and BM-17) that had
satisfactory RNA integrity numbers (RINs; Table 1, see also RNA
quality control section in MATERIALS AND METHODS). The
PCR quantification curves for control, house keeping gene 18S
rRNA (Figures S2A, S3A, S3C) and for Capzb2 (Figure S2, S3B,
S3D) were generated from each cDNA. Change in Cycle
Threshold (DCT) between the Capzb2 and the house keeping
gene 18S rRNA was calculated[23]. Two cDNA concentrations
(full strength and 1:2 dilution) were used to calculate DCT in order
to confirm that the obtained DCT values were consistent with the
cDNA concentrations. As duplicate samples were run, the average
CT value for Capzb2 was subtracted from the average CT value
for 18S rRNA, giving the DCT-Capzb2 value. The control brains’
cDNAs show higher DCT for Capzb2 than cDNAs from AD
BBIII-IV brains, indicating lower expression of Capzb2 in the
control brains (Figure 3).
Since the subset of CA1 pyramidal neurons in AD BB III-IV
displays defining AD intraneuronal cytoskeletal abnormalities,
neurofibrillary tangles (NFTs), we next examined Capzb2 mRNA
expression in relation to the presence of NFTs (Figure 4).
Approximately 1,500 tangled and 1,500 non-tangled CA1
pyramidal neurons from AD BBIII-IV (MADRC-1403, Table 1)
and 1,500 (non-tangled) CA1 pyramidal neurons from control
brains (BM16 and BM-17, Table 1) were dissected for qPCR
analysis (Figures 4 and S4). The mRNA levels of Capzb2 were
higher in both tangled and non-tangled neurons of the AD BBIII-
IV brain compared to the controls, while similar in tangled and
non-tangled neurons of the AD BBIII-IV brain (Figure 4C).
Because of their role in memory and cognition, BDNF and
TrkB have been previously studied in the brains of AD
patients[24–27], but without the information on Braak and Braak
stage of AD associated neuropathology. Braak and Braak staging,
introduced in 1997 and widely accepted thereafter, is based on the
extent of cortical involvement by neurofibrillary tangles[28]. Using
LCM and qPCR, we examined the expression of BDNF and TrkB
mRNAs in the developing, mid-stage (BBIII-IV), rather than in
the end-stage (BBVI) AD[24] (see DISCUSSION). Similar to
Capzb2, the mRNA level of TrkB in the CA1 neurons in AD
BBIII-IV brains was higher than that in the control brains
(Figures 5 and S5).
Discussion
We previously demonstrated that RNAi-mediated silencing of
Capzb2 in cultured hippocampal neurons resulted in short,
dystrophic neurites[9] reminiscent of the cytoskeletal changes
associated with neurodegeneration in AD. Cytoskeletal abnormal-
ities that included dystrophic neurites, decreased dendritic areas,
and decreased spine numbers have been described in hippocampal
neurons of mice that carried an APP transgene with multiple
mutations associated with familial AD[29]. Whereas at 3 months of
age APP transgenic hippocampal neurons showed no cytoskeletal
abnormalities, at 11 months of age evidence of degeneration existed
in all the parameters examined. Many neurons displayed dystrophic
neurites, reduced dendritic arborization, and loss of spines[29].
Most intriguing, however, were data suggestive of regenerative
activity at a time-point in between - at 8 months of age, as rare
dystrophic neurites became noticeable, a small increase in the
number of spines and total dendritic area was observed in APP
AD Cytoskeletal Reorganization
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transgenic neurons in comparison to controls[29]. Dendritic
proliferation and sprouting in human AD brain have been observed
by Golgi impregnation[30] and by MAP2 and tau immunohisto-
chemistry highlighting growth cones present both in perisomatic
dendrites and in distal, dystrophic neurites[20]. Thus, an AD
transgenic model and a human diseased brain share the hallmark of
cytoskeletal reorganization underlying degenerative (dystrophic
neurites) as well as regenerative changes (sprouting of processes
and the presence of growth cones).
Here we report an increase in the expression of Capzb2, a
protein necessary for normal growth cone morphology and neurite
length[9], specifically in the hippocampal CA1 region at mid-stage
AD (BBIII-IV) (Figure 1). This increase in Capzb2 expression
could not have been aided by the astrocytic gliosis was less
prominent in AD BBIII-IV brains than in control brains (Figure 2).
Consistent with our findings are previously reported GFAP
mRNA age-related increase in archi- and neo-cortex of both rats
and humans[31]and widespread astrocytic gliosis in both Alzhei-
mer’s and normal aging cerebrum[32]. Important for our analysis
was the definition of normal, ‘‘control’’ cases considering that the
cognitive function appears to be degraded in the non-demented
individuals who do exhibit AD- related neuropathological
changes[33]. We performed tau immunohistochemistry on all of
the studied hippocampal blocks and considered as controls only
those without any neurofibrillary tangles (BB 0; Figures 1, 2, and
data not shown).
Table 1. Analyzed human autopsy brains.
Case number Diagnosis Age (yr) Sex Postmortem interval (hr) RNA Integrity Number (RIN)
BM-1 Normal 58 M 19
BM-6 Normal 65 M 4
BM-9 Normal 72 F 23
BM-16# Normal 73 F 26 4.5
BM-17# Normal 77 F 47 4.5
MADRC-1314 Normal 56 M 36
MADRC-1339 Normal 79 F 48
MADRC-1359* AD BB I 75 M NA
MADRC-1301 AD BB I-II 85 M 24
MADRC-1389 AD BB III-IV 69 N/A 24
MADRC-972 AD BB III-IV 81 M 11
MADRC-1323 AD BB III-IV 94 M 24 6.4
MADRC-912 AD BB IV 103 F 5 6
MADRC-1403# AD BB IV 88 F 24 5.8
MADRC-1515# AD BB IV 84 M 24
MADRC-1345 AD BB IV-V 91 F 10
MADRC-1372 AD BB V 74 F 8
MADRC-1377 AD BB V 78 M 24
MADRC-971 AD BB V 81 M 11
MADRC-1052 AD BB V-VI 103 F 5.5
MADRC-1058 AD BB VI 105 F 24
MADRC-1202 AD BB VI 90 F 42
MADRC-1269 AD BB VI 91 F 22
MADRC-1303 AD BB VI 73 F 24
MADRC-1307 AD BB VI 82 F 24
MADRC-1315 AD BB VI 64 F 9
MADRC-1325 AD BB VI 80 F 30
MADRC-1329 AD BB VI 56 F 24
MADRC-1331 AD BB VI 81 F 24
MADRC-1341 AD BB VI 85 F 18
MADRC-1344 AD BB VI 69 M 5
MADRC-1353 AD BB VI 52 F 23
MADRC-1357 AD BB VI 87 M 6
MADRC-1360 AD BB VI 88 F 31
MADRC-1363 AD BB VI 77 M 12
*only PFC tissue was available;
#only HPC tissue analyzed.
doi:10.1371/journal.pone.0013337.t001
AD Cytoskeletal Reorganization
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The protein expression analysis of the CA1 region is supported by
the data on Capzb2 mRNA expression in hippocampal CA1
neurons obtained via LCM (Figure 3). Several pathologic features of
AD make cell population expression profiling a rational alternative
to whole brain homogenates: 1) defined vulnerable neuronal
populations; 2) distinct intracellular abnormalities found in some
but not all of the cells; and 3) the poor understanding of the
relationship between the presence of distinct extra- and intra-
cellular abnormalities and neuronal function and survival. The
importance of cell population expression profiles is in their potential
to identify new rational targets for pharmacotherapeutic interven-
tions in progressive neurodegenerative disorders such as AD.
Mature brain derived neurotrophic factor or BDNF shows high-
affinity binding to the neurotrophic tyrosine kinase receptor TrkB.
Figure 1. Capzb2 protein expression changes specifically in the hippocampal CA1 region (HPC) during progression of AD. (A)
Capzb2 protein levels in PFC do not change significantly during the progressive stages of AD in comparison to control cases; (B) Capzb2 protein levels
in HPC in AD BBIII-IV are significantly increased in comparison to control brains (**p,0.01, One-way ANOVA with subsequent Tukey’s test); (C) when
normalized to the expression in control brains, two unrelated proteins used as loading controls (GAPDH and histone H2b, His H2b) do not differ
significantly in their level of expression in the hippocampal CA1 region regardless of the AD stage. Hippocampal sections of the representative cases
form the progressive AD stages were processed for Capzb2 (D,F,H) and tau immunohistochemistry (E,G,I). As the AD progresses, neurofibrillary
tangles highlighted by tau immunohistochemistry accumulate (E,G,I). and the density of CA1 pyramidal neurons decreases (D–I). Capzb2 signal is
seen in the cytoplasms and neuropil, and appears stronger in AD BBIII-IV stage (arrows, F) in comparison to both normal control (BB 0; D) and
advanced disease (AD BBV-VI; H). The asterisk in E indicates the direction of pial surface in D–I.
doi:10.1371/journal.pone.0013337.g001
AD Cytoskeletal Reorganization
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The molecular basis for new learning is a rapid effect on synaptic
transmission (short-term memory) followed by persistent changes,
such as long-term potentiation, across neuronal synapses (synaptic
plasticity) that consolidate long-term memories. BDNF appears to
facilitate both synaptic transmission and long-term potentiation in
glutamergic hippocampal synapses acting through post-synaptic
TrkB receptors[34]. Conditional knock-out mice lacking forebrain
TrkB and mice treated with blocking antibodies to hippocampal
BDNF[35] show decreased development of LTP and impaired
learning. Animal studies suggest that as b-amyloid accumulates in
the hippocampus, it interferes with the normal function of
BDNF[36]. One clinical study suggested that patients with AD
have low whereas those with mild cognitive impairment (a stage
preceding clinical dementia) had intermediate BDNF levels
compared to normal controls[37]; others have suggested raised
BDNF levels in early AD[38,39]. A well-documented role of
BDNF/TrkB signaling in memory formation and retention via
cytoskeletal reorganization[16,17] has been driving the interest in
studying the expression of these molecules in relation to AD
pathological hallmarks[24]. Using immunohistochemical double-
labeling, Fujimura et al. (2010) showed that the number of tangled
neurons that expressed BDNF was similar in AD and controls[24].
In the same study, quantitative RT-PCR analysis of AD and control
hippocampal neurons, revealed that the expressions of BDNF and
TrkB in AD were equally low in Ab-containing and Ab-free
neurons and lower than that in control brains[24]. Importantly, the
three AD cases examined were all in advanced BB stages (VI, VI,
and V). Considering that a fully developed neurodegenerative
process may obscure the mechanisms driving the disease progres-
sion, we examined the expression of BDNF and TrkB mRNAs in
mid-stage AD (BBIII-IV) when Capzb2 was specifically up-
regulated (Figure 1, 2, 3, and 4). Similar to Capzb2, the expression
of TrkB in hippocampal CA1 neurons in AD BBIII-IV hippocampi
was higher than that in the control (Figure 5). Importantly, our
control hippocampi did not contain neurofibrillary tangles or
dystrophic neurites (Figure 4A) whereas the three cases used as
controls by Fujimura at al. (2010) did demonstrate AD-related
changes: two brains were categorized as BBI and one as BBII[24].
Understanding the role of BDNF/TrkB signaling in AD
pathogenesis could be of great clinical and public health
Figure 2. Reactive astrogliosis in CA1 region of AD BBIII-IV does not contribute to the increased Capzb2 expression. The number of
GFAP positive cells (A–C; bar in A, B =50 mm), as well as the analysis of GFAP signal by Western Blot (D) and by Luminex capture sandwich
immunoassay (E) indicate more reactive astrogliosis in control than in AD BB III-IV brains.
doi:10.1371/journal.pone.0013337.g002
AD Cytoskeletal Reorganization
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importance since BDNF is inducible and may be one of the key
molecules mediating the beneficial effect of certain lifestyle
measures (lower caloric intake, increased aerobic physical activity,
environmental enrichment)[40–42]on the risk of developing
dementia. These modifiable environmental interventions increase
brain and serum BDNF levels[43–46]. Aerobic exercise for
example induces both short-term and longer-term increases in
circulating BDNF levels, in parallel with improvements in memory
performance[47].
Our study shows that the expression of TrkB and Capzb2
mRNAs in hippocampal CA1 pyramidal neurons during mid-
stage AD (BBIII-IV) is up-regulated in comparison to the control
hippocampus containing no AD- related cytoskeletal abnormalities
(Figure 3, 4, and 5). Similar levels of Capzb2 mRNA expression in
tangled and non-tangled neurons in mid-stage AD (Figure 4)
support the observations that both populations undergo cytoskel-
etal reorganization that includes regenerative changes[20,30]. It is
conceivable that the progression of AD and concomitant
cytoskeletal reorganization is accompanied by the expression of
molecular markers of endogenous neuronal resistance to degen-
eration and/or molecular markers of regeneration. The expression
of these markers may reflect neuronal changes associated with
regeneration and possibly memory performance warranting future
Figure 3. Capzb2 mRNA expression in CA1 pyramidal neurons
of AD BBIII-IV is increased in comparison to control. Control
brains (BM-16 and BM-17) cDNA shows higher DCT for Capzb2 gene
than for the average of two AD BBIII-IV brains (MADRC-912 and MADRC-
1323); **p,0.01, Student’s t test.
doi:10.1371/journal.pone.0013337.g003
Figure 4. Capzb2 mRNA expression in CA1 pyramidal neurons is increased in AD BBIII-IV regardless of NFTs presence. NFTs are
absent from the population of pyramidal neurons dissected from the control CA1 region (A), whereas moderate number of tangles are found in the
pyramidal neurons dissected from AD BBIII-IV CA1 region (B; both tangled and non-tangled neurons as well as numerous dystrophic neurites are
present). (C) cDNA of control CA1 pyramidal (non-tangled) neurons shows higher DCT value than the cDNAs from either tangled or non-tangled CA1
pyramidal neurons from AD BBIII-IV brain (**p,0.01; One-way ANOVA with subsequent Tukey’s test); tangled and non-tangled CA1 pyramidal
neurons at AD BBIII-IV have similar DCT values.
doi:10.1371/journal.pone.0013337.g004
AD Cytoskeletal Reorganization
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correlation studies with the cognitive status information in
individual AD patients.
Methods
Ethics Statement
The Institutional Review Board at Boston University School of
Medicine provided an exemption for the protocol describing
research on postmortem human brain tissue analyzed in this study.
We examined the hippocampal CA1 region (HPC) and the
prefrontal cortex (PFC, Brodmann area 9) available from the
brains deposited at Massachusetts Alzheimer Disease Research
Center (MADRC) at Massachusetts General Hospital and from
brain autopsies performed at Boston Medical Center (BM),
(Table 1).
Immunohistochemistry
Hippocampal blocks (level of lateral geniculate nucleus) were
fixed in 4% paraformaldehyde and embedded in paraffin. For
detection of Capzb2 signal in hippocampal CA1 neurons, 10-mm
sections were incubated with an affinity isolated anti-CAPZB
antibody produced in rabbit (designed for immunohistochemistry
application, Sigma-Aldrich, 1:100) for 30 min at RT, washed in
phosphate buffered saline (pH 7.4; PBS), incubated with a
secondary antibody (Universal HRP multimer containing cocktail
of HRP labeled goat anti-rabbit) and visualized by DAB
(Figure 1D, 1F, 1H). For the detection of reactive astrocytes,
sections were incubated with a rabbit polyclonal anti-GFAP
antibody (1: 2,000, Dako) overnight at 4uC, washed in PBS,
incubated with a secondary antibody (Universal HRP multimer
containing cocktail of HRP labeled goat anti-rabbit) and visualized
by DAB (Figure 2A and 2B). Tiled images (470 mm 6470 mm)
were acquired from the CA1 region under the 20x magnification.
GFAP- immunoreactive astrocytes were counted in 20 tiled images
from the CA1 region (a total area of 4.42 mm2).
For the detection of neurofibrillary tangles (Figure 1E, 1G, 1I,
4A and 4B), paraffin sections were incubated with anti-tau
antibody (rabbit polyclonal, 1: 5,000, Dako, or mouse monoclonal,
PHF-1, 1:1,000; a gift from Dr. Peter Davies) overnight at 4uC,
washed with PBS, incubated with a secondary antibody incubation
(Super Sensitive Link Label IHC Detection Systems kit, Biogenex)
and visualized by DAB. Slides were counterstained with
hematoxylin and dehydrated with ethanol and xylene. Before
laser capturing to obtain neurons for qPCR analysis in Figure 4,
10-mm frozen sections were incubated with the same anti-tau
antibody (PHF-1, 1:50) for 10 min on ice, washed with PBS,
incubated with anti-mouse IgG HRP (Pierce, 1:50) for 10 min and
visualized by DAB. Slides were counterstained with hematoxylin
and dehydrated with ethanol and xylene.
Western Blot
The whole tissue lysates of hippocampal CA1 regions were
prepared in RIPA buffer containing protease inhibitors (Roche).
The final protein concentration of the lysates were determined by
BCA assay. Lysates were subjected to SDS-PAGE and immuno-
blotting with anti-Capzb2 (DSHB, 1: 1,000), anti-GFAP (Sigma, 1:
1,500), anti-histone H2B (Abcam, 1: 2,000), and anti-GAPDH
(Ambion, 1:10,000) using appropriate secondary HRP-conjugated
antibodies at 1:5,000 (Santa Cruz) (6 repetitions). A chemilumi-
nescent detection system (Pierce) was used to visualize protein
expression on an electronic capture imager (Kodak). Densitometry
measurements were performed using ImageJ version 1.37v
software (National Institutes of Health). For Capzb2 expression,
values were calculated as (intensity x area of Capzb2 signal)/
(intensity x area of GAPDH signal) (Figure 1A and 1B). In
Figure 1C the expressions (intensity x area of signal) of two
unrelated proteins (GAPDH and Histone H2b) in each BB group
were normalized to their expressions in the control group.
Luminex analysis
A mouse monocolonal GFAP antibody (GFAP mAb, 25 mg,
Sigma) was coupled to 1.25 million Microplex microspheres 133
(Luminex) using EDC (Thermo Scientific) and Sulfo-NHS
(Thermo Scientific) as directed by the manufacturer protocol. A
rabbit polyclonal GFAP antibody (GFAP pAb, 145 mg, Dako) was
coupled to biotin using EZ-link Sulfo-NHS-LC-Biotin reagent
(Pierce) as directed by the manufacturer protocol. Brain lysates
(0.5 mg/50 ml) were incubated with 50 ml of GFAP mAb-
microspheres (100 MS/ml) in a 100 ml reaction for 30 min at
room temperature (RT) in a 1.2 mm filter plate (Millipore) with
agitation. The GFAP mAb-microspheres were washed twice with
PBS-1%BSA and resuspended in 50 ml PBS-1% BSA. 50 ul of
GFAP pAb-biotin (50 ml, 1 mg/ml) was then added and the
mixture was incubated at RT for 30 min. Microspheres were then
washed twice, resuspended in 50 ml PBS-1% BSA and 50 ml of
Streptavidin-R-phycoerythrin reporter (Invitrogen) (4 mg/ml), and
incubated for 30 min at RT. Upon another wash, the microsphere
complexes were resuspended in 100 ml of PBS-1% BSA and
analyzed on a Luminex 200. GFAP expression was reported as the
mean fluorescence signal per 100 microspheres. The assay was
performed three times.
Figure 5. The expression of TrkB mRNAs in CA1 pyramidal neurons of AD BBIII-IV is increased in comparison to control. The cDNA
from two control brains (BB0; BM-16 and BM-17) CA1 pyramidal neurons has higher DCT value for TrkB (A) in comparison to the average of two AD
BBIII-IV (MADRC-912 and MADRC-1323) values indicating lower amount of TrkB mRNA; *p,0.05, Student’s t test. BDNF mRNA levels in the examined
AD BB III-IV cases are not significantly different from those found in control cases (B).
doi:10.1371/journal.pone.0013337.g005
AD Cytoskeletal Reorganization
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RNA quality control
We have examined the RNA quality of the hippocampal blocks
used for LCM and subsequent qPCR analysis by the commonly
accepted quantitative digital analysis of Agilent 2100 Bioanalyzer
generated electropherograms. The resulting RNA Integrity
Number (RIN) of 1 (poor) to 10 (best) is obtained based on the
presence and ratio of the 5S, 18S and 28S ribosomal RNA peaks
in a sample of total cellular RNA. Banked postmortem brain
tissues across institutions have been reported to display range of
RIN values from 2.9 to 9.2 (mean =6.8+/2 1.0)[48]. We have
found that even partially degraded RNA with a RIN value of 3.1
shows fairly well preserved mRNA profile (unpublished data). The
hippocampi used for qPCR displayed RIN values from 4.5 to 6.4
(Table 1).
Laser Capture Microdissection (LCM)
In preparation for LCM, frozen blocks of the hippocampal
tissue (level of the lateral geniculate) were oriented and affixed to
cryotome chucks with OCT embedding compound. Ten mm
cryosections were stained to visualize cells (Figure S1). We found
that approximately 2,000 CA1 pyramidal neurons yielded enough
cDNA for qPCR of four genes (our genes of interest - Capzb2,
BDNF, TrkB - and housekeeping gene, 18S rRNA). Veritas LCM
system was used to collect CA1 pyramidal neurons onto optically
clear collecting caps that contain a thin plastic film impregnated
with a laser sensitive dye. Caps were placed over the area of
interest and illuminated with a monochromatic IR laser pulse
which selectively heats the plastic/dye combination at a set size
(sizes are set anywhere between a diameter of 4 and 50 mm) and
lifts the precisely microdissected underlying tissue when the cap is
lifted. The isolated material was viewed to verify its integrity before
RNA extraction. For the visualization of neurons, each section was
lightly fixed in 70% ethanol (EtOH), rinsed with RNase-free
dH2O, incubated in HistoGene stain solution (MDS Analytical
Technologies), and dehydrated in ethanol solutions and xylene.
For the visualization of neurofibrillary tangles, see Immunohisto-
chemistry section. After neurons were collected, RNA was prepared
using the Arcturus picopure RNA isolation system (Arcturus, MDS
Analytical Technologies). Briefly, plastic LCM collecting caps with
captured neurons were incubated at 42uC for 30 minutes in 25 ml
of GITC-containing extraction buffer. After brief centrifugation,
tubes containing the extraction buffer were frozen at -80uC.
Samples are thawed and pooled prior to purification on Picopure
RNA columns. The RNAs from the cell homogenate were
attached to the column filter. After DNase treatment, genomic
DNA was removed. Total cellular RNA from each column was
eluted in 12 ml of elution buffer. RNA was converted into cDNAs
using a 20 ml total reaction volume via the Standard Superscript
III (Invitrogen) protocol for qPCR analysis.
Primer design and qPCR analysis
For Capzb2 PCR, multiple pairs of primers were generated by
the Primer3 software and produced by Invitrogen. The PCR
products obtained with these primers were tested in Bioanalzyer
gel and Bioanalzyer Electropherograms (Figure S2). The successful
Capzb2 primers (forward: gcaaatcgagaaaaacctca; reverse:
ctccaagggagggtcatact) were used in qPCR analysis. Similarly,
successful primers for BDNF (forward: cagctgccttgatggttact;
reverse: ccaatgatgtcaagcctctt) and TrkB (forward: ggacgtgtacag-
cactgact; reverse: tgccataggtgaaaatctcc) were obtained. All the
primers were tested using standard cDNA from normal human
brain as template provided by ATRC Reagent Bank. The Bank
also provided primers for PCR of 18S rRNA, a house keeping
gene often used as an internal control.
Statistical analysis
One way ANOVA analysis was performed in multiple groups
comparisons (Figure 1 and 4C) except for the comparison between
the control group and BB stage I-II in Figure 1B where Student’s t
test was performed because of only one hippocampus specimen
(Table 1). Student’s t test was also performed in the rest of the
statistical analysis where two groups/samples were compared
(Figure 2C, 2D, 2E, 3, 4C, and 5).
Supporting Information
Figure S1 Hippocampal CA1 region prepared for LCM of
pyramidal neurons. Visualization of the cells using HistoGene
stain at 2x (A: area magnified from the red square on the insert)
and 20x (B: pyramidal neurons are identified for capturing by
LCM).
Found at: doi:10.1371/journal.pone.0013337.s001 (3.54 MB TIF)
Figure S2 Bioanalyzer gel of PCR products obtained with
primers for Capzb2 and 18S rRNA genes (A) and electrophero-
gram for Capzb2 PCR product (B). The bioanalyzer gel indicates
the correct sizes of PCR products: Capzb2 -198 bp, and 18S
rRNA -177 bp. The electropherogram shows the number of
fluorescent units (FU) on the Y axis that corresponds with each bp
size on the X axis. The highest peak is at 198 bp (the correct size
of Capzb2 PCR product).
Found at: doi:10.1371/journal.pone.0013337.s002 (1.45 MB TIF)
Figure S3 qPCRs for 18S rRNA (A, C) and Capzb2 (B, D).
These figures complement Figure 3. The Y axis shows the
amplification and the X axis shows the number of cycles. Each line
traces the amplification of either full strength or 1:2 diluted cDNA
from analyzed cases: BM-16 (control, BB0), BM-17 (control, BB0),
MADRC-912 (AD BBIII-IV), and MADRC-1323 (AD BBIII-IV).
Reactions with dilutions of each cDNA were run in duplicates.
qPCRs for 18S rRNA for control cases (A) show control case BM-
16 in navy (full strength) and blue (1:2 dilution) and control case
BM-17 in dark green (full strength) and light green (1:2 dilution).
The same shades are used for Capzb2 qPCRs in those cases (B).
qPCRs in AD BBIII-IV cases for 18S rRNA (C) and for Capzb2
(D) show AD BBIV case MADRC-912 in navy (full strength) and
blue (1:2 dilution); AD BBIII-IV case MADRC-1323 is shown in
dark green (full strength) and light green (1:2 dilution).
Found at: doi:10.1371/journal.pone.0013337.s003 (1.67 MB TIF)
Figure S4 qPCRs for 18S rRNA (A, B) and Capzb2 (C, D).
These figures complement Figure 4. Each line traces the
amplification of either full strength or 1:2 diluted cDNA (shades
of the same color; in duplicates) in non-tangled neurons from
control (BB0) cases BM-16 (full strength -navy; 1:2 dilution -blue)
and BM-17 (full strength -dark green; 1:2 dilution -light green) for
18S rRNA (A) and Capzb2 (C). qPCRs for 18S rRNA in tangled
neurons from AD BBIV case MADRC-1403 is in navy (full
strength) and blue (1:2 dilution) and in non-tangled neurons from
the same section in dark green (full strength) and light green (1:2
dilution) (B). qPCRs for Capzb2 in tangled (full strength -navy;
1:2 dilution -blue) and non-tangled (full strength -dark green; 1:2
dilution -light green) neurons of AD BBIV case MADRC-1403
(D).
Found at: doi:10.1371/journal.pone.0013337.s004 (1.71 MB TIF)
Figure S5 qPCRs for 18S rRNA in control cases (A, E) and in
AD BBIII-IV cases (C, G); BDNF in control (B) and AD BBIII-IV
(D) cases; TrkB in control (F) and AD BBIII-IV (H) cases. These
figures complement Figure 5. Each line traces the amplification of
either full strength or 1:2 diluted of analyzed control cases (BM-16
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and BM-17) and AD BBIII-IV cases (MADRC-912 and MADRC-
1323). Reactions with dilutions of each cDNA were run in
duplicates. Navy (full strength) and blue (1:2 dilution) labelings are
used for amplicons from control case BM-16 (A, B, E, F) and from
AD BBIV case MADRC-912 (C, D, G, H). Shades of green are
amplicons from control case BM-17 (A, B, E, F) and from AD
BBIV case MADRC-1323 (C, D, G, H) (full strength -dark green;
1:2 dilution -light green).
Found at: doi:10.1371/journal.pone.0013337.s005 (3.43 MB TIF)
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